T. Rowe Price Investment Management, Inc. Crispr Therapeutics Ag Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,737,470 shares of CRSP stock, worth $127 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
2,737,470
Previous 2,730,652
0.25%
Holding current value
$127 Million
Previous $147 Million
12.8%
% of portfolio
0.08%
Previous 0.09%
Shares
9 transactions
Others Institutions Holding CRSP
# of Institutions
491Shares Held
58MCall Options Held
1.1MPut Options Held
1.9M-
Capital International Investors Los Angeles, CA7.93MShares$367 Million0.07% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$347 Million3.35% of portfolio
-
State Street Corp Boston, MA2.99MShares$139 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.97MShares$137 Million0.1% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$137 Million1.61% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.61B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....